thiazoles has been researched along with ponesimod in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 37 (66.07) | 24.3611 |
| 2020's | 19 (33.93) | 2.80 |
| Authors | Studies |
|---|---|
| Abele, S; Binkert, C; Bolli, MH; Bravo, R; Buchmann, S; Bur, D; Gatfield, J; Hess, P; Kohl, C; Mangold, C; Mathys, B; Menyhart, K; Müller, C; Nayler, O; Scherz, M; Schmidt, G; Sippel, V; Steiner, B; Strasser, D; Treiber, A; Weller, T | 1 |
| Bolli, MH; Clozel, M; Froidevaux, S; Hess, P; Kohl, C; Nayler, O; Piali, L; Schlosser, E; Steiner, B | 1 |
| Bauer, Y; Bolli, MH; Gatfield, J; Killer, N; Menyhart, K; Nayler, O; Renault, B; Sobel, K; Steiner, B; Studer, R | 1 |
| Brossard, P; Derendorf, H; Dingemanse, J; Halabi, A; Maatouk, H; Xu, J | 1 |
| Clozel, M; Delahaye, S; Gatfield, J; Hess, P; Nayler, O; Rey, M; Steiner, B | 1 |
| Bach, JF; Chatenoud, L; Clozel, M; Kuhn, C; Piali, L; Sauvaget, V; Steiner, B; Valette, F; You, S | 1 |
| Brossard, P; Chassard, D; Dingemanse, J; Hoch, M; Reyes, M | 1 |
| Brossard, P; Dingemanse, J; Halabi, A; Krause, A; Maatouk, H; Scherz, M | 1 |
| Bach, D; Berkani, O; Boster, A; Fernández, Ó; Freedman, MS; Melanson, M; Mueller, MS; Olsson, T; Pozzilli, C; Radue, EW; Sidorenko, T | 1 |
| Kuwabara, S; Mori, M | 1 |
| Bolli, MH; Gatfield, J; Monnier, L; Nayler, O; Steiner, B; Studer, R | 1 |
| Bieberich, E; Bryant, L; Chen, C; Chen, Z; Cuzzocrea, S; Doyle, T; Esposito, E; Janes, K; Kamocki, K; Li, C; Little, JW; Neumann, WL; Nicol, G; Obeid, L; Petrache, I; Salvemini, D; Snider, A | 1 |
| Brossard, P; D'Ambrosio, D; Dingemanse, J; Krause, A | 1 |
| Brossard, P; D'Ambrosio, D; Dingemanse, J; Hoch, M; Wilbraham, D | 1 |
| Menter, A; Ryan, C | 1 |
| Arenberger, P; Burcklen, M; Chimenti, S; D'Ambrosio, D; Holló, P; Sator, PG; Stefani, M; Vaclavkova, A | 1 |
| Brossard, P; Dingemanse, J; Hoch, M; Miraval, T; Reyes, M; Wagner-Redeker, W | 1 |
| Brossard, P; Darpo, B; Dingemanse, J; Hoch, M; Stoltz, R; Zhou, M | 1 |
| Brossard, P; Dingemanse, J; Hoch, M; Reyes, M | 1 |
| Brossard, P; D'Ambrosio, D; Dingemanse, J; Steinmann, J | 1 |
| Brossard, P; D'Ambrosio, D; Dingemanse, J; Ipek, M; Scherz, MW | 1 |
| D'Ambrosio, D; Dingemanse, J; Hoch, M; Juif, PE | 1 |
| Dingemanse, J; Guérard, N; Hoch, M; Zwingelstein, C | 1 |
| Warren, RB; Yiu, ZZ | 1 |
| Dingemanse, J; Krause, A; Lehr, T; Lott, D | 2 |
| Bush, J; Dingemanse, J; Hoch, M; Juif, PE; Krause, A; Vaclavkova, A | 1 |
| Sadik, CD; Thieme, M; Zillikens, D | 1 |
| Dingemanse, J; Krause, A; Lehr, T; Lott, D; Seemayer, CA; Strasser, DS | 1 |
| Reddy, SP; Wu, JJ | 1 |
| Dash, RP; Rais, R; Srinivas, NR | 1 |
| Chaudhry, BZ; Cohen, JA; Conway, DS | 1 |
| D'Ambrosio, D; Dingemanse, J; Krause, A | 1 |
| Bell, M; Epemolu, O; Foley, D; Katz, E; McLean, WHI; Naylor, C; Read, KD; Riley, J; Robinson, C; Scullion, P; Shishikura, Y; Woodland, A; Wyatt, P | 1 |
| Armstrong, AW; Singh, S | 1 |
| Bar-Or, A; Filippi, M; Piehl, F; Preziosa, P; Rocca, MA; Solari, A; Vukusic, S | 1 |
| Dingemanse, J; Juif, PE; Ufer, M | 1 |
| Baldin, E; Lugaresi, A | 1 |
| Anzai, I; Fauzyah, Y; Fukuhara, T; Izumi, T; Maeda, Y; Matsuura, Y; Morioka, Y; Okamoto, T; Ono, C; Suzuki, R; Torii, S | 1 |
| Burcklen, M; D'Ambrosio, D; Fox, RJ; Freedman, MS; Havrdová, EK; Hennessy, B; Hohlfeld, R; Kappos, L; Kracker, H; Linscheid, P; Lublin, F; Montalban, X; Pirozek-Lawniczek, M; Pozzilli, C; Scherz, T; Sprenger, T; Vaclavkova, A | 1 |
| Leirens, Q; Ouwerkerk-Mahadevan, S; Pérez-Ruixo, JJ; Poggesi, I; Valenzuela, B | 1 |
| Burcklen, M; Gisleskog, PO; Pérez-Ruixo, JJ; Poggesi, I; Scherz, T; Valenzuela, B | 1 |
| Markham, A | 1 |
| Gao, M; Guo, L; Hou, H; Miao, J; Song, X; Sun, Y | 1 |
| Guo, K; Jiang, Y; Liao, Y; Peng, J; Yin, S; Zhang, L; Zhang, X; Zhou, J | 1 |
| Cohen, JA; McGinley, MP | 1 |
| Ianniello, A; Pozzilli, C | 1 |
| Chun, J; Jonnalagadda, D; Kihara, Y; Ngo, T; Palmer, C; Ray, M; Rivera, R; Zhu, Y | 1 |
| Burcklen, M; Freedman, MS; Havrdova, EK; Hennessy, B; Larbalestier, A; Lemle, A; Olsson, T; Pozzilli, C; Sidorenko, T; Vaclavkova, A | 1 |
| Burcklen, M; Kracker, H; Olsson Gisleskog, P; Pérez-Ruixo, JJ; Poggesi, I; Sidorenko, T; Valenzuela, B | 1 |
| Alnaif, A; D'Souza, MS; Oiler, I | 1 |
| Luyckx, N; Pérez-Ruixo, JJ; Poggesi, I; Vaclavkova, A; Valenzuela, B | 1 |
| Asensio Sánchez, S; García Ródenas, MDM; Gómez Román, M; Moreno Navarro, L; Pérez Sempere, Á | 1 |
| Kruger, TM; Ouwerkerk-Mahadevan, S; Ruixo, JJP; Thompson, CD; Valenzuela, B | 1 |
13 review(s) available for thiazoles and ponesimod
| Article | Year |
|---|---|
Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Topics: Adamantane; Adenosine; Adenosine A3 Receptor Antagonists; Administration, Oral; Arthritis, Psoriatic; Azetidines; Biological Factors; Biological Therapy; Clinical Trials as Topic; Humans; Isonicotinic Acids; Janus Kinases; Niacinamide; Phosphodiesterase 4 Inhibitors; Piperidines; Protein Kinase Inhibitors; Psoriasis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Lysosphingolipid; rho-Associated Kinases; Sulfonamides; Thalidomide; Thiazoles | 2016 |
Sphingosine-1-phosphate modulators in inflammatory skin diseases - lining up for clinical translation.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Receptors, Lymphocyte Homing; Receptors, Lysophospholipid; Skin Diseases; Sphingosine; Thiazoles | 2017 |
Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P
Topics: Clinical Trials as Topic; Drug Compounding; Food-Drug Interactions; Humans; Models, Biological; Receptors, Lysosphingolipid; Thiazoles | 2017 |
Ponesimod, a selective sphingosine 1-phosphate (S1P
Topics: Autoimmune Diseases; Dosage Forms; Dose-Response Relationship, Drug; Drug Interactions; Humans; Receptors, Lysosphingolipid; Thiazoles | 2018 |
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
Topics: Animals; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Indans; Indoles; Multiple Sclerosis; Naphthalenes; Oxadiazoles; Propanolamines; Receptors, Lysosphingolipid; Thiazoles; Treatment Outcome | 2017 |
Oral small molecules for psoriasis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Humans; Patient Selection; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Thalidomide; Thiazoles | 2018 |
Multiple sclerosis.
Topics: Azetidines; Benzyl Compounds; Demyelinating Diseases; Humans; Indans; Magnetic Resonance Imaging; Multiple Sclerosis; Oxadiazoles; Risk Factors; Thiazoles; Tomography, X-Ray Computed | 2018 |
Ponesimod for the treatment of relapsing multiple sclerosis.
Topics: Administration, Oral; Clinical Trials as Topic; Humans; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Thiazoles; Treatment Outcome | 2020 |
Ponesimod: First Approval.
Topics: Animals; Clinical Trials, Phase III as Topic; Humans; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Sphingosine-1-Phosphate Receptors; Thiazoles | 2021 |
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
Topics: Animals; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immune System Diseases; Indans; Multiple Sclerosis; Nervous System Diseases; Oxadiazoles; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Thiazoles | 2021 |
Ponesimod to treat multiple sclerosis.
Topics: Humans; Multiple Sclerosis; Receptors, Lysosphingolipid; Recurrence; Thiazoles | 2021 |
Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis.
Topics: Humans; Immunologic Factors; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiazoles | 2023 |
Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis.
Topics: Humans; Immunologic Factors; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Thiazoles | 2023 |
18 trial(s) available for thiazoles and ponesimod
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Immunologic Factors; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Models, Biological; Receptors, Lysosphingolipid; Thiazoles; Young Adult | 2013 |
Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive.
Topics: Adult; Area Under Curve; Contraceptives, Oral, Combined; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Heart Rate; Humans; Middle Aged; Norethindrone; Receptors, Lysosphingolipid; Thiazoles; Time Factors | 2014 |
Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lymphocyte Count; Male; Middle Aged; Models, Biological; Receptors, Lysosphingolipid; Thiazoles; Young Adult | 2014 |
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Severity of Illness Index; Thiazoles; Young Adult | 2014 |
Clinical pharmacology of ponesimod, a selective S1P₁ receptor modulator, after uptitration to supratherapeutic doses in healthy subjects.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Receptors, Lysosphingolipid; Thiazoles; Young Adult | 2014 |
Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Administration, Oral; Chronic Disease; Double-Blind Method; Humans; Psoriasis; Thiazoles; Treatment Outcome | 2014 |
Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.
Topics: Action Potentials; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Fluoroquinolones; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Receptors, Lysosphingolipid; Risk Assessment; Sphingosine-1-Phosphate Receptors; Thiazoles; Time Factors; Young Adult | 2015 |
Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects.
Topics: Adult; Asian People; Female; Humans; Lymphocyte Count; Male; Receptors, Lysosphingolipid; Thiazoles; White People | 2014 |
Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations.
Topics: Antigens, CD20; B-Lymphocytes; CD3 Complex; Dose-Response Relationship, Drug; Double-Blind Method; Flow Cytometry; GPI-Linked Proteins; Healthy Volunteers; Humans; Lymphocyte Count; Male; Receptors, IgG; Receptors, Lysosphingolipid; T-Lymphocyte Subsets; Thiazoles | 2015 |
Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Lymphocytes; Male; Middle Aged; No-Observed-Adverse-Effect Level; Receptors, Lysosphingolipid; Thiazoles; Young Adult | 2015 |
Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects.
Topics: Adult; Area Under Curve; Biological Availability; Capsules; Chemistry, Pharmaceutical; Cross-Over Studies; Female; Healthy Volunteers; Humans; Male; Receptors, Lysosphingolipid; Tablets; Therapeutic Equivalency; Thiazoles | 2015 |
Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor Modulator.
Topics: Adult; Area Under Curve; Case-Control Studies; Female; Humans; Liver Diseases; Male; Middle Aged; Receptors, Lysosphingolipid; Renal Insufficiency; Severity of Illness Index; Thiazoles; Thiazolidines | 2016 |
Mitigation of Initial Cardiodynamic Effects of the S1P
Topics: Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Healthy Volunteers; Heart Rate; Hemodynamics; Humans; Lymphocyte Count; Male; Middle Aged; Receptors, Lysosphingolipid; Thiazoles; Young Adult | 2017 |
Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis.
Topics: Clinical Trials, Phase III as Topic; Computer Simulation; Dose-Response Relationship, Drug; Humans; Lymphocyte Count; Models, Biological; Patient Selection; Placebos; Psoriasis; Receptors, Lysosphingolipid; Severity of Illness Index; Thiazoles; Treatment Outcome | 2018 |
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Crotonates; Disease Progression; Female; Humans; Hydroxybutyrates; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Nitriles; Thiazoles; Toluidines; Young Adult | 2021 |
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.
Topics: Humans; Infant; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Thiazoles; Treatment Outcome | 2021 |
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
Topics: Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Thiazoles; Treatment Outcome | 2022 |
An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.
Topics: Adult; Crotonates; Humans; Hydroxybutyrates; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Recurrence; Thiazoles; Toluidines; Treatment Outcome | 2022 |
25 other study(ies) available for thiazoles and ponesimod
| Article | Year |
|---|---|
2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.
Topics: Administration, Oral; Animals; Cell Line; Cricetinae; Cricetulus; Dogs; Hepatocytes; High-Throughput Screening Assays; Humans; Imines; Lymphocyte Count; Male; Microsomes, Liver; Radioligand Assay; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidines | 2010 |
The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Hypersensitivity, Delayed; Inflammation; Lymphocyte Count; Lymphocyte Subsets; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Monocytes; Rats; Rats, Inbred Lew; Rats, Wistar; Receptors, Lysosphingolipid; Thiazoles | 2011 |
Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling.
Topics: Actins; Animals; CHO Cells; Cricetinae; Cricetulus; Down-Regulation; Extracellular Matrix; Humans; Lung; Lysophospholipids; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myofibroblasts; Organophosphates; Oxadiazoles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pulmonary Fibrosis; Receptors, Lysosphingolipid; Signal Transduction; Smad2 Protein; Smad3 Protein; Sphingosine; Thiazoles; Thiophenes; Transforming Growth Factor beta1 | 2013 |
Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator.
Topics: Administration, Oral; Animals; Atrioventricular Block; Atrioventricular Node; Blood Pressure; Drug Tolerance; Electrocardiography; Guinea Pigs; Heart; Heart Rate; Male; Receptors, Lysosphingolipid; Thiazoles | 2013 |
Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes.
Topics: Administration, Oral; Adoptive Transfer; Animals; Antibodies; B-Lymphocytes; CD3 Complex; Diabetes Mellitus, Type 1; Drug Administration Schedule; Gene Expression; Glucose-6-Phosphatase; Hypoglycemic Agents; Lymph Nodes; Lymphocyte Count; Mice; Mice, Inbred NOD; Receptors, Lysosphingolipid; Recurrence; Self Tolerance; Spleen; T-Lymphocytes; Thiazoles | 2013 |
Are more sphingosine 1-phosphate receptor agonists a better therapeutic option against multiple sclerosis?
Topics: Female; Humans; Male; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Thiazoles | 2014 |
Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.
Topics: Arrestins; Autoimmune Diseases; beta-Arrestins; Cell Line, Tumor; GTP-Binding Protein alpha Subunits, Gi-Go; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Lysophospholipids; Membrane Proteins; Phosphoric Monoester Hydrolases; Protein Transport; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; T-Lymphocytes; Thiazoles | 2014 |
The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.
Topics: Anilides; Animals; Antineoplastic Agents, Phytogenic; Cytokines; Enzyme Activation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Indans; Lysophospholipids; Male; Neuralgia; Organophosphonates; Oxadiazoles; Paclitaxel; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiazoles; Thiophenes | 2014 |
Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator.
Topics: Adolescent; Adult; Aged; Body Weight; Circadian Rhythm; Female; Humans; Intestinal Absorption; Lymphocyte Count; Male; Middle Aged; Models, Statistical; Multiple Sclerosis; Population; Receptors, Lysosphingolipid; Thiazoles; Young Adult | 2014 |
Ponesimod--a future oral therapy for psoriasis?
Topics: Humans; Psoriasis; Thiazoles | 2014 |
Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans.
Topics: Administration, Oral; Humans; Male; Middle Aged; Receptors, Lysosphingolipid; Scintillation Counting; Thiazoles | 2015 |
Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.
Topics: Adult; Female; Humans; Kidney; Liver; Male; Middle Aged; Receptors, Lysosphingolipid; Thiazoles; Young Adult | 2016 |
Modeling the Effect of the Selective S1P
Topics: Adolescent; Adult; B-Lymphocytes; Circadian Rhythm; Computer Simulation; Dose-Response Relationship, Drug; Female; Humans; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Models, Biological; Receptors, Lysosphingolipid; T-Lymphocytes; Thiazoles; Young Adult | 2017 |
Oral ponesimod for psoriasis compared to other investigational therapies.
Topics: Biological Factors; Humans; Psoriasis; Severity of Illness Index; Therapies, Investigational; Thiazoles | 2016 |
Discovery of super soft-drug modulators of sphingosine-1-phosphate receptor 1.
Topics: Administration, Topical; Aryldialkylphosphatase; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Discovery; Esterases; Humans; Receptors, Lysosphingolipid; Skin; Solubility; Sphingosine-1-Phosphate Receptors; Structure-Activity Relationship; Thiazoles | 2018 |
Cardiodynamic Interactions between Two S1P
Topics: Adult; Double-Blind Method; Electrocardiography, Ambulatory; Female; Half-Life; Healthy Volunteers; Heart Rate; Humans; Lymphocyte Count; Male; Random Allocation; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Thiazoles; Young Adult | 2019 |
Ponesimod suppresses hepatitis B virus infection by inhibiting endosome maturation.
Topics: Antiviral Agents; DNA, Viral; Endosomes; HEK293 Cells; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Hepatocytes; Humans; Sphingosine-1-Phosphate Receptors; Thiazoles; Virus Internalization; Virus Replication | 2021 |
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis.
Topics: Humans; Lymphocyte Count; Lymphocytes; Multiple Sclerosis; Thiazoles | 2021 |
Ponesimod modulates the Th1/Th17/Treg cell balance and ameliorates disease in experimental autoimmune encephalomyelitis.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Inflammation Mediators; Mice; Mice, Inbred C57BL; Sphingosine 1 Phosphate Receptor Modulators; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Thiazoles | 2021 |
Ponesimod.
Topics: Administration, Oral; Humans; Thiazoles | 2021 |
Ponesimod protects against neuronal death by suppressing the activation of A1 astrocytes in early brain injury after experimental subarachnoid hemorrhage.
Topics: Animals; Astrocytes; Brain Injuries; Cell Death; Cell Polarity; Encephalitis; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Psychomotor Performance; Signal Transduction; Sphingosine-1-Phosphate Receptors; STAT3 Transcription Factor; Subarachnoid Hemorrhage; Thiazoles | 2021 |
Ponesimod (Ponvory) for multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Humans; Hydroxybutyrates; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Randomized Controlled Trials as Topic; Sphingosine 1 Phosphate Receptor Modulators; Thiazoles; Toluidines; United States; United States Food and Drug Administration | 2021 |
Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P
Topics: Animals; Astrocytes; Cell Line, Tumor; Cells, Cultured; Central Nervous System; Humans; Male; Mice; Mice, Inbred C57BL; Neuroinflammatory Diseases; Protective Agents; Signal Transduction; Sphingosine-1-Phosphate Receptors; Thiazoles | 2022 |
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis.
Topics: Heart Rate; Humans; Multiple Sclerosis; Receptors, Lysosphingolipid; Thiazoles | 2023 |
Dyspnea and Bronchoconstriction in a Young Patient With Multiple Sclerosis Treated With Ponesimod.
Topics: Bronchoconstriction; Dyspnea; Humans; Multiple Sclerosis; Thiazoles | 2023 |